EOD Primary Tumor

Notes

**Note 1:** For skin, patch indicates any size skin lesion without significant elevation or induration. **Note 2:** For skin, plaque indicates any size skin lesion that is elevated or indurated. **Note 3:** For skin, tumor indicates at least one 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. **Note 4:** Sezary syndrome is the leukemic form of Mycosis Fungoides. EOD Primary Tumor for Sezary syndrome is still coded based on the amount/type of skin involvement. Peripheral blood involvement, which is indicative of the leukemic variant, is coded in Peripheral Blood Involvement [NAACCR Data Item #3910]
Code Description SS2018 T
100 Less than 10% of skin surface, no tumors - Patches only L
150 Less than 10% of skin surface, no tumors - Papules or plaques WITH or WITHOUT patches L
200 Skin involvement less than 10% OR unknown % of skin involvement - AND not stated whether patches, papules or plaques - AND no tumors Limited skin involvement Localized, NOS MFCG Stage I L
250 Greater than or equal to 10% of skin surface, no tumors - Patches only L
300 Greater than or equal to 10% of skin surface, no tumors - Plaques or papules WITH or WITHOUT patches L
400 Skin involvement greater than or equal to 10% Generalized plaques/patches OR Not stated whether patches, papules or plaques No tumors MFCG Stage II L
450 Generalized erythroderma (confluence of erythemia) (Greater than 50% and less than 80% body surface involved with diffuse redness) RE
500 Skin lesion described as tumor less than 1 cm RE
600 One or more tumors equal to 1 cm or greater Cutaneous tumor, size not stated MFCG Stage III RE
700 Generalized erythroderma (confluence of erythemia) (Greater than or equal to 80% body surface involved with diffuse redness) RE
800 No evidence of primary tumor U
999 Unknown; extension not stated Primary tumor cannot be assessed Not documented in patient record Death Certificate Only U
(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998 (2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. (3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL) (4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 3-30 (5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 931-935 (6) Rosen, S.T., Jaffe, E.S., Leonard, J.P., et al. **Primary Cutaneous Lymphomas**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 967-972